Patent ID: 9566280
Date: 2017-02-14
CPC Classifications: A61K,A61P

Claim:
1. A method of treating a patient with cancer comprising administering to the patient an effective amount of abiraterone or abiraterone acetate in combination with an effective amount of a polo-like kinase inhibitor (PLK), wherein the abiraterone or abiraterone acetate and the polo-like kinase inhibitor are administered simultaneous or wherein the abiraterone or abiraterone acetate is administered to the patient 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, or 24 hours, 1, 2, 3, 4, 5, 6, or 7 days, 1, 2, 3, or 4 weeks, prior to administration of the polo-like kinase inhibitor to the patient, and wherein administration of the combination of abiraterone or abiraterone acetate and the polo-like kinase inhibitor is effective to reduce cancer cell proliferation or viability in the patient to a greater degree than administering to the patient the same amount of abiraterone or abiraterone acetate alone or the same amount of polo-like kinase inhibitor alone.